Five things for pharma marketers to know: Tuesday, June 28, 2016

1. Bristol-Myers Squibb's Opdivo received its sixth Breakthrough Therapy designation from the FDA for bladder cancer. (Pharmatimes)

2. AstraZeneca is trying to block generic competition for its cholesterol-lowering treatment Crestor by getting it approved to treat a rare disease. The British drugmaker is looking for the seven additional years of market exclusivity given under the Orphan Drug Act. (NYT)

3. Endo International is considering selling some of its assets. The drugmaker has discussed the potential sale of some its products to reduce its debts, according to unnamed sources cited by Reuters. (Reuters)

4. Medtronic has agreed to acquire HeartWare International for $1.1 billion, a devicemaker that makes surgical implants that mimic heart functions. (WSJ)

5. The FDA and European Medicines Agency accepted a marketing application for Roche's Ocrevus, an experimental multiple-sclerosis treatment. The drug also received Priority Review status Tuesday from the FDA. (Reuters)